NeuroSense Therapeutics Ltd.(NRSN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
NRSN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for NeuroSense Therapeutics Ltd. (NRSN), a Healthcare sector company. NRSN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (FY 2025), NeuroSense Therapeutics Ltd. reports net income of $-11.1M, free cash flow of $-7.7M. Top institutional holders of NRSN by reported 13-F value include Yorkville Advisors Global,, Independent Advisor Alliance, UBS Group AG, based on the most recent SEC filings. NRSN trades on the Nasdaq exchange and files with the SEC under CIK 1875091. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRSN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NeuroSense Therapeutics Ltd. directly from SEC EDGAR.
Net Income
FY 2025
$-11.1M
Free Cash Flow
FY 2025
$-7.7M
Get alerted when NRSN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for NeuroSense Therapeutics Ltd. including:
Top Institutional Holders of NRSN
Yorkville Advisors Global, LP
$58.9K78,000 shIndependent Advisor Alliance
$37.8K50,000 shUBS Group AG
$37.1K49,096 shTWO SIGMA INVESTMENTS, LP
$33.6K44,445 shMEITAV INVESTMENT HOUSE LTD
$30.2K40,000 shJANE STREET GROUP, LLC
$21.6K28,670 shEmpery Asset Management, LP
$20.1K100,402 shCOMMONWEALTH EQUITY SERVICES, LLC
$17.2K22,775 shPNC FINANCIAL SERVICES GROUP, INC.
$16.0K21,150 shClear Street Group Inc.
$12.7K63,385 sh
| Fund | Value | Shares |
|---|---|---|
| Yorkville Advisors Global, LP | $58.9K | 78,000 |
| Independent Advisor Alliance | $37.8K | 50,000 |
| UBS Group AG | $37.1K | 49,096 |
| TWO SIGMA INVESTMENTS, LP | $33.6K | 44,445 |
| MEITAV INVESTMENT HOUSE LTD | $30.2K | 40,000 |
| JANE STREET GROUP, LLC | $21.6K | 28,670 |
| Empery Asset Management, LP | $20.1K | 100,402 |
| COMMONWEALTH EQUITY SERVICES, LLC | $17.2K | 22,775 |
| PNC FINANCIAL SERVICES GROUP, INC. | $16.0K | 21,150 |
| Clear Street Group Inc. | $12.7K | 63,385 |
More Healthcare Companies
View all Healthcare →Put NRSN on your watchlist
Track score changes the day NeuroSense Therapeutics Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is NRSN a good stock to buy?
13F Pro's AI-powered analysis of NeuroSense Therapeutics Ltd. (NRSN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NRSN are available on the NRSN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own NRSN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NRSN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NeuroSense Therapeutics Ltd.'s investment landscape.